Vorasidenib first may help chemo and radiation work better in mice
Original title: Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
The main result was in mice, with only a small, early look at people.
The short version
In mice with a type of brain tumor, taking the drug vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary first seemed to help chemo and radiation work better later.
What was studied. Researchers used mice bred to grow IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary astrocytoma, a kind of brain tumor. Some mice got vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary first and then chemo and radiation when the tumor grew again. Other mice got no drug first, then the same chemo and radiation.
What they found. The mice that got vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary first lived longer than the mice that did not. The researchers also showed the mouse tumors responded to vorasidenib on its own. They then gathered early real world information from 29 patients who were among the first to get this drug before radiation, with or without chemo.
What this means, and what it doesn't
What it could mean: Doctors are not sure what order these treatments should come in. This work is one early piece of that puzzle. It hints that starting with vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary may not hurt later chemo and radiation, and may even help. It does not change how you are treated today. Your care team decides the order based on your own situation.
What it doesn't mean: This is not a cure, and it is not proof for people. The main result came from mice, not from patients. Mouse results often do not carry over to people. The information from the 29 patients is early and was only collected as they went, not from a real trial that compared groups. Nothing here means you should ask to change the order of your treatment.
Source: PubMed, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.